Cardiology Business

Edwards Acquires JenaValve and Endotronix, Expands into Aortic Regurgitation and Heart Failure

Edwards Lifesciences is going all-in on structural heart and heart failure, acquiring aortic valve-maker JenaValve Technology and implantable heart failure monitor company Endotronix for $1.2B and up to $445M in milestone payments.

These two acquisitions could impact Edwards’ structural heart and heart failure portfolios in unique and meaningful ways…

JenaValve’s Trilogy TAVR system doesn’t yet have FDA approval, but is CE Marked for both aortic regurgitation and aortic stenosis, which is notable given that all other TAVR systems only address aortic stenosis.

  • The JenaValve Trilogy could gain FDA approval for aortic regurgitation by late 2025, complementing Edwards’ already strong aortic stenosis capabilities.

Endotronix recently landed FDA approval for its Cordella heart failure sensor, which combines an implanted PA sensor to measure congestion, a handheld PA pressure reader, and a digital health platform to enable comprehensive home-based HF management. 

  • The Cordella system could have a major impact, given the success of its PROACTIVE-HF trial, and its anticipated nationwide coverage by CMS in early 2025.

These acquisitions also confirm that Edwards is in the middle of an M&A spree, as they come just a few weeks after it acquired early-stage TMVR company Innovalve Bio Medical for $300M and invested $16M in surgical mitral valve startup Affluent Medical.

In fact, Edwards likely has more M&A coming up, noting that it just sold its Critical Care business to BD for $4.2B, pledging to use the influx of capital to “to fund strategic growth investments” targeting structural heart, pulmonology, and interventional heart failure technologies.

Although these recent acquisitions aren’t expected to have a major impact on Edwards’ finances until at least 2026, their success is crucial in the long term, noting that Edwards just reported a slowdown in its flagship TAVR business that sent the stock plummeting 31%.

The Takeaway

Edwards made it clear that it was going to use its Critical Care cash to drive strategic growth, and it hasn’t taken long to put that plan into action, acquiring its way into key growth areas for the company and the overall cardiac device segment.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Electrophysiology August 21, 2025

Conduction-System Pacing Succeeds at Treating AV Block August 21, 2025

Conduction-system pacing could be poised to reshape standard care for atrioventricular (AV) block patients after the randomized CSPACE trial demonstrated its significant benefits over traditional right ventricular septal pacing. Taking a closer look at CSP’s potential, the CSPACE trial enrolled 202 patients with AV block at two Australian hospitals, randomizing them to conduction-system pacing or […]

Cardiology Pharmaceuticals August 18, 2025

Rivaroxaban Monotherapy Could Be Better for CAD + AFib August 18, 2025

New analysis from the AFIRE trial suggests rivaroxaban monotherapy might be emerging as a preferred antithrombotic strategy for patients with AFib and stable coronary artery disease, especially in older age groups. The Post Hoc AFIRE Analysis examined 2,215 Japanese patients with AFib and stable CAD, stratifying them into four age groups (<70, 70-74, 75-79, and […]

Surgeries & Interventions August 14, 2025

TEER Could Save Lives in AFMR Patients August 14, 2025

Shedding light on a new treatment for an understudied condition, data published in EHJ suggests that transcatheter edge-to-edge repair (TEER) delivers significant survival advantages in patients with atrial functional mitral regurgitation (FMR). The new OCEAN-Mitral/REVEAL-AFMR Analysis compared 441 TEER-treated patients against 640 medically managed controls with moderate or severe atrial FMR, stating a solid case […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!